ELVN Is Moving Fast on CML Data

Let’s talk about a clinical-stage biotech that just had a very good week.

Enliven Therapeutics (Nasdaq: ELVN) presented updated Phase 1 data for its lead asset, ELVN-001, at the European Hematology Association (EHA) 2026 Congress in Stockholm on June 11. The stock responded. ELVN ripped roughly 15% to around $42.50 after the data drop, and the stock is now trading near the top of its 52-week range and above its 200-day simple moving average. That is not a random move. There is data behind it.

What the Numbers Actually Say

ELVN-001 is targeting chronic myeloid leukemia (CML) – specifically patients who have already failed available therapies. This is a hard patient population. These are not first-line cases.

As of the March 10, 2026 cutoff date, 161 patients were enrolled in the ongoing Phase 1 trial across dose levels ranging from 10 to 240 mg daily. Most patients (76%) remain on study with a median treatment duration of 35 weeks. Patients enrolled were heavily pretreated, with 70% having received three or more prior unique TKIs and 23% having received five or more unique TKIs.

At the selected 80 mg once-daily dose – the dose the FDA has now signed off on – the results were the strongest yet. The 80 mg once-daily group produced a 61% overall major molecular response (MMR) rate, with 48% of evaluable patients achieving MMR within 24 weeks, and deep molecular response rates reached 30% in this cohort. Among less heavily pretreated patients, the numbers were even cleaner: in those who had received one or two prior TKIs, overall MMR reached 67%, while 55% achieved MMR by 24 weeks.

The safety profile held up. Only 6% of patients discontinued due to adverse events, with most toxicities being Grade 1 or 2, while Grade 3 or higher events were limited and less frequent at the 80 mg dose.

The FDA Part Matters More Than the Data

Good Phase 1 data in biotech is nice. FDA alignment is better. Enliven reached alignment with the FDA on the 80 mg once-daily dose and the inclusion of patients who have received at least one prior TKI in the planned ENABLE-2 Phase 3 trial. That removes a major design uncertainty. ENABLE-2, Enliven’s planned Phase 3 trial, is expected to begin in the second half of 2026, with final design elements to follow additional FDA discussions including an End-of-Phase 2 meeting targeted for the third quarter of 2026.

Phase 3 initiation is now a when, not an if. That changes the risk calculus.

Balance Sheet and the New Capital Raise

The company also moved fast on capital. A large primary offering priced at $37.50 per share raised substantial cash, announced the same day as the updated positive Phase 1 ENABLE data. Proceeds will advance ELVN-001, including initiation of ENABLE-2, and the company projects that combined proceeds and existing cash will fund operations into 2030.

Before the raise, the picture was already clean. The balance sheet showed approximately $452.4M in cash and short-term investments against only $11.5M in total liabilities, with a current ratio over 40. ELVN posted roughly $23.6M in Q1 2026 net loss, with about $20.7M of that going into research and development. No revenue yet – that is standard for a company at this stage – but the runway is not a concern.

What Wall Street Is Saying

Guggenheim has a price target of $80, Stifel at $60, and Mizuho at $62, with all three leaning on the same thesis: ELVN-001 can carve out a meaningful role in CML, particularly for resistant disease. Mizuho raised its price target from $45 to $62 following the reported clinical updates.

Slight tangent: the leadership team got a significant upgrade going into this stretch. Rick Fair joined as CEO in December 2025 and Scott Garland was added to the Board in January 2026, with the company explicitly framing these changes as aligning experienced leadership with its transition into late-stage development and future commercialization. That kind of bench matters when you are heading into a Phase 3 program.

The Cheap Investor Scorecard

• ENABLE Phase 1b: 161 patients enrolled, 76% still on study at cutoff
• 80 mg QD dose: 61% overall MMR, 48% MMR by 24 weeks, 30% deep molecular response
• Less pretreated cohort (1-2 prior TKIs): 67% overall MMR, 55% by 24 weeks
• Discontinuation rate due to adverse events: 6% – favorable profile
• FDA aligned on 80 mg QD dose and 2L+ patient population for ENABLE-2
• Phase 3 ENABLE-2 initiation expected second half of 2026
• End-of-Phase 2 FDA meeting targeted Q3 2026
• Cash and equivalents: $452.4M pre-offering; post-offering runway projected into 2030
• Q1 2026 R&D spend: $20.7M – disciplined relative to pipeline stage
• Analyst price targets: $60 (Stifel), $62 (Mizuho), $80 (Guggenheim)

The risks are real. ELVN-001 has no approved product, no revenue, and Phase 3 trials are not guaranteed. Cross-trial comparisons are imperfect. CML is a competitive space. If Phase 3 enrollment drags or the design shifts materially after the Q3 FDA meeting, this story gets harder to own.

But the data keeps improving with each update, the FDA is engaged, the balance sheet is arguably the strongest it has ever been, and the company is now building commercial leadership ahead of a registrational readout. That is a different kind of biotech than the ones running on fumes and hope.

Watch the ENABLE-2 launch date. That is where the next real signal comes from.